no, it's not. It's for short-term use to treat anaemia caused by chemotherapy. Some doctors were prescribing it for off-label use to treat long-term anaermia. There's now a specific black box warning regarding that practice, since it's not effective and it increased mortality rates:
http://www.fda.gov/Drugs/DrugSafety...ormationforPatientsandProviders/ucm200297.htm
Epogen®/Procrit® is indicated for the treatment of anemia due to the effect of concomitantly administered chemotherapy, based on studies that have shown a reduction in the need for red blood cell transfusions in patients with metastatic, non-myeloid malignancies receiving chemotherapy for a minimum of 2 months.
ESAs are not indicated for use in patients receiving hormonal agents, therapeutic biologic products, or radiotherapy unless receiving concomitant myelosuppressive chemotherapy.
ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.
ESA use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being.
Along with the mountains of research which have led to this, there's a lot more which has yet to be published, or the publication of which is currently in dispute, because drug companies have a lot of money and ESAs are big business. The entire EPO situation makes the UCI look like an upright organization.
Regardless, is the new news that it was a blood transfusion gone bad?